Tiziana Life Sciences PLC (LON:TILS – Get Free Report) shares passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 58.50 ($0.76) and traded as low as GBX 45 ($0.59). Tiziana Life Sciences shares last traded at GBX 58.50 ($0.76), with a volume of 297,127 shares changing hands.
Tiziana Life Sciences Trading Up 8.3 %
The company has a debt-to-equity ratio of 2.36, a current ratio of 6.54 and a quick ratio of 6.41. The firm has a market capitalization of £113.85 million and a PE ratio of -3.59. The company’s fifty day simple moving average is GBX 58.50 and its 200-day simple moving average is GBX 58.50.
About Tiziana Life Sciences
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. Its product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma.
Read More
- Five stocks we like better than Tiziana Life Sciences
- How to Evaluate a Stock Before Buying
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Investing In Preferred Stock vs. Common Stock
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.